Key result
Sorafenib significantly increased the risk of hypertension (RR 2.93; 95% CI 1.52-5.66), bleeding (RR 2.42), and left ventricular dysfunction (RR 9.38) compared with controls.
Why the study?
Does daily sorafenib treatment increase the risk of cardiovascular toxicities in patients with solid tumors?
Meta-Analysis
Does daily sorafenib treatment increase the risk of cardiovascular toxicities in patients with solid tumors?
Sorafenib treatment in patients with solid tumors significantly increases the risk of cardiovascular toxicities, particularly hypertension, bleeding, and left ventricular dysfunction.
Sorafenib warrants cardiovascular monitoring in solid tumors; confirms substantial cardiotoxicity risks via Level 1 evidence.
BACKGROUND: We performed a systematic review and meta-analysis of cardiovascular toxicities associated with sorafenib. PATIENTS & METHODS: Eligible studies included randomized Phase II and III trials of patients with solid tumors receiving daily sorafenib treatment that described the following events: hypertension, bleeding, venous thromboembolism, left ventricular dysfunction myocardial ischemia and cerebrovascular events. RESULTS: A total of 18 randomized clinical trials were considered eligible for the meta-analysis. Patients treated with sorafenib had a significantly increased risk of hypertension (relative risk [RR]: 2.93; 95% CI: 1.52-5.66), bleeding (RR: 2.42; 95% CI: 1.63-3.62) and left ventricular dysfunction (RR: 9.38; 95% CI: 1.24-71.22). The risk for venous thromboembolism, myocardial ischemia and cerebrovascular events was nonsignificant. Subgroup analyses showed that tumor type and treatment regimen had no effect on the RR of cardiovascular toxicities. CONCLUSION: Our meta-analysis demonstrated that sorafenib is associated with a higher risk of developing all grade hypertension and bleeding compared with controls.
No takes yet. Share an insight, caveat, or question.
Abdel‐Rahman et al. (2014) conducted a meta-analysis in Solid tumors. Sorafenib vs. controls was evaluated on Hypertension (RR 2.93, 95% CI 1.52-5.66). Sorafenib significantly increased the risk of hypertension (RR 2.93; 95% CI 1.52-5.66), bleeding (RR 2.42), and left ventricular dysfunction (RR 9.38) compared with controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: